Incyte, Merck to conduct tests on epacadostat and Keytruda combination treatment
Incyte Corp. and Merck will work together to study the combination of epacadostat and Keytruda in people fighting several types of cancer.
The study will look at melanoma that has spread, nonsmall-cell lung cancer, bladder cancer, renal cell carcinoma, and head and neck squamous cell carcinoma, according to a news announcement.
They have started on a Phase 3 test on melanoma that has spread. Additionally, the companies will work on two Phase 3 tests of the medications as the first treatments of nonsmall-cell lung cancer and two tests of the medicines for fighting bladder cancer. One of the bladder cancer tests will use the epacadostat and Keytruda as the initial treatments for the disease and the other that will use the medicines as a second set of fighters of the disease. A Phase 3 test for renal cell carcinoma and head and neck squamous cell carcinoma will also be conducted, and the medicines will be used as the initial treatments for the diseases.
Incyte and Merck will fund the tests, while Merck will perform the tests.